P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy
出版年份 2021 全文链接
标题
P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy
作者
关键词
Virus-like particle (VLP), Antigen delivery, Cancer vaccine, Cytotoxic T-Lymphocyte (CTL)
出版物
BIOMATERIALS
Volume 271, Issue -, Pages 120726
出版商
Elsevier BV
发表日期
2021-02-21
DOI
10.1016/j.biomaterials.2021.120726
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cutting Edge: Protection by Antiviral Memory CD8 T Cells Requires Rapidly Produced Antigen in Large Amounts
- (2018) Sanda Remakus et al. JOURNAL OF IMMUNOLOGY
- A facile approach to enhance antigen response for personalized cancer vaccination
- (2018) Aileen Weiwei Li et al. NATURE MATERIALS
- Personalized vaccines for cancer immunotherapy
- (2018) Ugur Sahin et al. SCIENCE
- Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1
- (2018) Yong Gao et al. Frontiers in Immunology
- Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses
- (2018) Jiale Liu et al. ACS Applied Materials & Interfaces
- Personalized tumor vaccines keep cancer in check
- (2017) Jocelyn Kaiser SCIENCE
- Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy
- (2017) Guizhi Zhu et al. Nature Communications
- Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
- (2017) Guizhi Zhu et al. Nature Communications
- Virus like particles as a platform for cancer vaccine development
- (2017) Hui Kian Ong et al. PeerJ
- Rethinking cancer nanotheranostics
- (2017) Hongmin Chen et al. Nature Reviews Materials
- Design of virus-based nanomaterials for medicine, biotechnology, and energy
- (2016) Amy M. Wen et al. CHEMICAL SOCIETY REVIEWS
- Mutanome directed cancer immunotherapy
- (2016) Mathias Vormehr et al. CURRENT OPINION IN IMMUNOLOGY
- Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer
- (2016) Sabrin H. Albeituni et al. JOURNAL OF IMMUNOLOGY
- Neoantigen landscape dynamics during human melanoma–T cell interactions
- (2016) Els M. E. Verdegaal et al. NATURE
- Designer vaccine nanodiscs for personalized cancer immunotherapy
- (2016) Rui Kuai et al. NATURE MATERIALS
- Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
- (2016) Qian Chen et al. Nature Communications
- pH-Responsive Poly(d,l-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response
- (2015) Qi Liu et al. ACS Nano
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Therapeutic cancer vaccines
- (2015) Cornelis J.M. Melief et al. JOURNAL OF CLINICAL INVESTIGATION
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer
- (2015) Sebastian Kreiter et al. NATURE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Developing Genetically Engineered Encapsulin Protein Cage Nanoparticles as a Targeted Delivery Nanoplatform
- (2014) Hyojin Moon et al. BIOMACROMOLECULES
- Immune responses to vaccines involving a combined antigen–nanoparticle mixture and nanoparticle-encapsulated antigen formulation
- (2014) Weifeng Zhang et al. BIOMATERIALS
- Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
- (2014) M. Rajasagi et al. BLOOD
- Functionalization of protein-based nanocages for drug delivery applications
- (2014) Lise Schoonen et al. Nanoscale
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
- (2014) Mahesh Yadav et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- RGD-Modified Apoferritin Nanoparticles for Efficient Drug Delivery to Tumors
- (2013) Zipeng Zhen et al. ACS Nano
- Biomimetic Antigenic Nanoparticles Elicit Controlled Protective Immune Response to Influenza
- (2013) Dustin P. Patterson et al. ACS Nano
- Location of the Bacteriophage P22 Coat Protein C-Terminus Provides Opportunities for the Design of Capsid-Based Materials
- (2013) Amy Servid et al. BIOMACROMOLECULES
- β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells
- (2013) Jie Tian et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Use of the interior cavity of the P22 capsid for site-specific initiation of atom-transfer radical polymerization with high-density cargo loading
- (2012) Janice Lucon et al. Nature Chemistry
- Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development
- (2012) Natasha Kushnir et al. VACCINE
- Genetically Programmed In Vivo Packaging of Protein Cargo and Its Controlled Release from Bacteriophage P22
- (2011) Alison O'Neil et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Self-Assembled Virus-Like Particles from Rotavirus Structural Protein VP6 for Targeted Drug Delivery
- (2011) Qinghuan Zhao et al. BIOCONJUGATE CHEMISTRY
- Functional Virus-Based Polymer–Protein Nanoparticles by Atom Transfer Radical Polymerization
- (2011) Jonathan K. Pokorski et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Virus-like particles in vaccine development
- (2010) António Roldão et al. Expert Review of Vaccines
- Macrophage activation and polarization
- (2007) Fernando Oneissi Martinez Frontiers in Bioscience-Landmark
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started